Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma

Table 1

Association of NEIL3 level with clinicopathological parameters of HCC patients.

Parameters	All patients	NEIL3 expression		χ^2	value
	(n = 130)	High (n = 68)	Low (n = 62)
Gender				0.494	0.482
Male	102	55	47
Female	28	13	15
Age (years)				0.226	0.634
≤55	79	40	39
>55	51	28	23
HBsAg				1.379	0.240
Negative	22	9	13
Positive	108	59	49
Cirrhosis				1.336	0.248
Negative	24	10	14
Positive	106	58	48
AFP (ng/mL)				1.706	0.192
≤20	45	20	25
>20	85	48	37
Tumor size (cm)				2.473	0.116
≤5	64	29	35
>5	66	39	27
Tumor number				0.001	0.991
Solitary	88	46	42
Multiple	42	22	20
Tumor differentiation				1.270	0.260
I‐II	73	35	38
III‐IV	57	33	24
TNM stage				7.915	0.005
I‐II	94	42	52
III‐IV	36	26	10
BCLC stage
0-A	84	36	48	8.499	0.004
B-C	46	32	14

NEIL3, Nei-like DNA glycosylase 3; HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; AFP, serum alpha-fetoprotein; TNM, tumor-nodes-metastasis; BCLC, Barcelona Clinic Liver Cancer. Bold values represent P < 0.05, which is statistically significant.